Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNDROS vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
FDA: Chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics,FDA: Anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS)
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life is 28–61 hours (mean ~32 hours) in adults; prolonged with high-fat meal. Clinical context: Steady state achieved in 5–6 days.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Primarily hepatic via cytochrome P450 (CYP) 3A4 and 2C9 isoenzymes; undergoes extensive first-pass metabolism to active and inactive metabolites.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Approximately 65% of a dose is excreted in feces (primarily as hydroxylated and carboxylated metabolites) and 35% in urine (as metabolites, with <5% unchanged drug).
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
97–99% bound, primarily to albumin and lipoproteins.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Vd: 10–80 L/kg (mean ~30 L/kg), indicating extensive tissue distribution.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral bioavailability: ~10–20% (variable due to extensive first-pass metabolism); increased 2- to 4-fold with a high-fat meal.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
No dose adjustment required for mild to moderate renal impairment; insufficient data for severe impairment (e GFR <30 m L/min); use with caution.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to potential for encephalopathy.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Safety and efficacy not established in pediatric patients; not recommended under 18 years.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
No specific dose adjustment; monitor for increased sensitivity to adverse effects (e.g., dysphoria, hypotension).
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
None
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Risk of psychiatric adverse reactions, including dysphoria, hallucinations, paranoia, and worsening of pre-existing mental illness,Central nervous system depressant effects and impairment of cognitive function, motor skills, and judgment; caution when driving or operating machinery,Potential for abuse, tolerance, and dependence (Schedule III controlled substance),May increase heart rate and blood pressure; use with caution in patients with cardiovascular disease,Seizures: May lower seizure threshold in patients with epilepsy,Pancreatitis: Cases reported; monitor for symptoms
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to dronabinol or any cannabinoid or sesame oil (capsule contains sesame oil),Concurrent use with disulfiram or metronidazole due to alcohol content in oral solution (however, Syndros is a dronabinol solution; contraindication applies to alcohol-containing formulations – note: Syndros contains alcohol; label contraindicates concurrent use with disulfiram or metronidazole)
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Food with high fat content may increase dronabinol absorption; take consistently with or without food to avoid variability. Grapefruit and grapefruit juice may increase dronabinol levels; avoid concurrent use.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
Dronabinol (SYNDROS) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a small increased risk of neural tube defects. Second and third trimester exposure may affect fetal brain development, including potential long-term neurobehavioral effects. Dronabinol crosses the placenta. Use only if potential benefit justifies potential risk to the fetus.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Dronabinol is excreted into human milk. The M/P ratio is not specifically determined for dronabinol; however, THC (active component) has an M/P ratio of approximately 0.04 based on limited data. Because of the potential for adverse effects on the nursing infant, such as developmental delay and sedation, breastfeeding is not recommended during SYNDROS therapy. An alternative method of infant feeding should be considered.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce dronabinol concentrations. However, due to lack of systematic dose-response data and potential fetal risks, routine dose increments are not recommended. The lowest effective dose should be used. If clinical response is suboptimal, consider non-pharmacologic alternatives. Do not exceed maximum recommended doses (20 mg/day).
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Syndros (dronabinol oral solution) is a synthetic delta-9-tetrahydrocannabinol (THC) used for chemotherapy-induced nausea and vomiting (CINV) and anorexia with weight loss in AIDS patients. It has a high first-pass metabolism; avoid use in patients with hepatic impairment. Onset is faster than capsules; dosing must be individualized based on prior cannabis exposure. Monitor for CNS depression and avoid concurrent use with other CNS depressants. Syndros contains alcohol (5% v/v); use cautiously in patients with alcohol intolerance or liver disease. Contraindicated in patients with a history of hypersensitivity to THC or sesame oil (vehicle).
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take Syndros 1 to 3 hours before chemotherapy for CINV, or twice daily before lunch and dinner for AIDS-related anorexia.,Avoid driving or operating machinery until you know how Syndros affects you, as it can cause dizziness, drowsiness, and altered judgment.,Do not drink alcohol or take other sedating medications while using Syndros, as this increases the risk of severe sedation.,Report any mood changes, depression, or suicidal thoughts to your healthcare provider immediately.,Store at room temperature (20-25°C) and protect from light; do not freeze.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss use with your doctor; THC can pass into breast milk.,Use a calibrated measuring device for the oral solution (provided with the medication) to ensure accurate dosing.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNDROS vs ALFENTANIL, answered by our medical review team.
SYNDROS is a Cannabinoid that works by Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNDROS and ALFENTANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNDROS is: 5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNDROS and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNDROS is classified as Category C. Dronabinol (SYNDROS) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses similar to human therapeutic doses. There are no . ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.